Coronavirus

HHS Announces Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron

WASHINGTON, D.C. — U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra recently announced that the federal government has purchased 600,000 treatment courses of a new monoclonal antibody …

HHS Announces Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron Read More

NRx Pharmaceuticals

NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) states it has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of …

NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant Read More

NRx Pharmaceuticals

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge Read More
Immunome

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced a recent update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Read More